Abstract

γδ T cells represent less than 5% of circulating T cells; they exert a potent cytotoxic function against tumor or infected cells and secrete cytokines like conventional αβ T cells. As αβ T cells γδ T cells reside in the typical T cell compartments (the lymph nodes and spleen), but are more widely distributed in tissues throughout the body. For these reasons, some investigators are exploring the possibility of immunotherapies aimed to expand and activate Vδ2 T cells, or using them as Chimeric Antigen Receptor carriers. However, the role of immunosuppressive microenvironment on Vδ2 T cells during infections and cancers has not been completely elucidated. In particular, the effects of myeloid-derived suppressor cells (MDSC), largely expanded in such pathologies, were not explored. In the present work, we demonstrated that MDSC may inhibit IFN-γ production and degranulation of phosphoantigen-activated Vδ2 T cells. Moreover, the Vδ2 T cells cytotoxic activity against the Burkitt lymphoma cell line Daudi and Jurkat cell line were impaired by MDSC. The Arginase I seems to be involved in the impairment of Vδ2 T cell function induced by both tumor cells and MDSC. These data open a key issue in the context of Vδ2-targeted immunoteraphy, suggesting the need of combined strategies aimed to boost Vδ2 T cells circumventing tumor- and MDSC-induced Vδ2 T cells suppression.

Highlights

  • It has been demonstrated that myeloid-derived suppressor cells (MDSC) are able to inhibit T cell activity, but little is known about MDSC/Vδ2 T cell relationship

  • The ability of MDSC to modulate Vδ2 T cell cytotoxicity and IFNγ production was evaluated by analyzing the expression of CD107a or IFN-γ on Vδ2 T cells after 18 h

  • Vδ2 T cells participate in the early stages of the immune response, they are able to recognize antigens displayed following infection or other forms of stress, and to respond to stress without requiring extensive clonal expansion

Read more

Summary

Introduction

Among peripheral CD3+ γδ T cells, those expressing a TCR formed by the Vγ9 and Vδ2 variable regions (hereafter referred to as Vδ2 T cells) constitute up to 90% of γδ T cells [2]. These Vδ2 T cells recognize non-peptidic phosphorylated metabolites of isoprenoid biosynthesis, present in most pathogenic bacteria [3], or isopentenyl pyrophosphate, produced by the human mevalonate biosynthesis pathway [4] that get accumulated in virus-infected and cancer cells due to alterations in the mevalonate pathway.

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call